Trade UroGen Pharma Ltd. - URGN CFD

Trading Conditions

• TypeThis financial market is available for CFD trading.Learn more about:CFDs: CFD
• Spread: 0.58
• Long position overnight funding adjustmentLong position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position-0.02240 %(-$1.12)Trade size with leverage ~ $5,000.00Money from leverage ~ $4,000.00Go to platform: -0.02240%
• Short position overnight funding adjustmentShort position overnight funding adjustmentMargin. Your investment$1,000.00Overnight funding adjustmentCharges from full value of position0.00018 %($0.01)Trade size with leverage ~ $5,000.00Money from leverage ~ $4,000.00Go to platform: 0.00018%
• Overnight funding adjustment time: 22:00 (UTC)
• Currency: USD
• Min traded quantity: 1
• Margin: 20.00%
• Stock exchange: United States of America
• Commission on trade: 0%
• Guaranteed stop premiumA guaranteed stop-loss (GSL) fee is only charged if the GSL is triggered. Please consult the Charges and Fees section of our website for more details.: 1%

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: -0.02240 %
  (-$1.12)

• Margin. Your investment: $1,000.00
• Overnight funding adjustmentCharges from full value of position: 0.00018 %
  ($0.01)

Key Stats

• Prev. Close: 34.38
• Open: 32.63
• 1-Year Change: 58.55%
• Day's Range: 27.83 - 32.63

Trade UroGen Pharma Ltd. - URGN

What is UroGen Pharma Ltd. (URGN)?

UroGen Pharma Ltd. is a biopharmaceutical company specializing in the development of innovative therapies for the treatment of uro-oncology and other medical conditions. The company focuses on delivering localized treatments that target diseases within the urinary tract, aiming to improve efficacy while minimizing systemic side effects. UroGen employs proprietary drug-delivery technologies designed to enhance the administration and retention of therapeutic agents in the bladder and other urological tissues. Its research and development efforts encompass various stages of clinical trials for products addressing bladder cancer and other urological disorders. The company operates within the biotechnology sector, collaborating with academic institutions and industry partners to advance its pipeline. UroGen's approach reflects a broader trend in precision medicine, emphasizing targeted treatment modalities. It is headquartered in Israel and maintains a presence in the United States, supporting its clinical and commercial activities. The organization contributes to the evolving landscape of cancer therapeutics through its specialized focus on urological diseases.

UroGen Pharma Ltd. Stock Price Today: Live Overview

The price today is shaped by ongoing trades, with Capricor Therapeutics Inc priced at $28.74. It has seen price movement between $27.4 and $33.52, posting a daily change of -19.7208%.

FAQ: UroGen Pharma Ltd. (URGN)

What is the current price of URGN stock?

UroGen Pharma Ltd.'s current price is $28.74.

Does URGN pay dividends?

UroGen Pharma Ltd. does not currently pay dividends.

Does URGN have a formal corporate presence or regional headquarters in the UAE?

UroGen Pharma Ltd. does not have an official office or subsidiary in the UAE and operates through partners.

What is URGN best known for?

UroGen Pharma Ltd. is most famous for its development of urological cancer treatments.

What assets are typically shown together with URGN?

Commonly shown alongside URGN: Wallbox N.V., ScotiaBank, Fletcher Building Limited